Cardiac safety of citalopram: Prospective trials and retrospective analyses

Journal of Clinical Psychopharmacology

Volumn 19, Issue 5, 1999, Pages 407-415

  Rasmussen, Søren Lind ^a   Overø, Kerstin F ^b   Tanghøj, Per ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ELECTROCARDIOGRAM; HEART CONDUCTION; HEART RATE; HEART REPOLARIZATION; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; ELECTROCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 0032822136     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199910000-00004     Document Type: Article

References (42)

1. Williams RB Jr, Sherter C. Cardiac complications of tricyclic antidepressant therapy. Ann Intern Med 1971;74:395-8.
2. Glassman AH, Bigger JT Jr. Cardiovascular effects of therapeutic doses of tricyclic antidepressants: a review. Arch Gen Psychiatry 1981;38:815-20.
3. Rawling DA, Fouzzard HA. Effects of imipramine on electrophysiological properties of cardiac Purkinje fibers. J Pharmacol Exp Ther 1979;209:371-5.
4. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84: 1831-51.
5. Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmia: a meta analysis. Circulation 1991;84:1977-83.
6. Glassman AH, Stage KB. Depressed patients with cardiovascular disease: treatment considerations. Pract Ther CNS Drugs 1994; 1:435-40.
7. Hyttel J, Arnt J, Sánchez C. The pharmacology of citalopram. Rev Contemp Pharmacother 1995;6:271-81.
8. Montgomery SA, Johnson FN. Citalopram in the treatment of depression. Rev Contemp Pharmacother 1995;6:297-306.
9. Baldwin D, Johnson FN. Tolerability and safety of citalopram. Rev Contemp Pharmacother 1995;6:315-25.
10. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder: a multicentre double-blind active (clomipramine) and placebo-controlled study. Br J Psychiatry 1997;170:549-53.
11. Overø KF, Højelse F. The unexpected preclinical finding - elucidation of dog toxicity - citalopram. In: Proceedings of the Association of the Swedish Pharmaceutical Industry workshop on the use of pharmacology studies in drug safety assessment - present situation and future perspectives. Stockholm, Sweden, Sep 26-27, 1994:113-5.
12. Baumann P, Larson F. The pharmacokinetics of citalopram. Rev Contemp Pharmacother 1995;6:287-95.
13. Sindrup S, Brøsen K, Hansen MGF, Aes-Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-7.
14. Feighner J, Overø K, Fieve R, Carman J, Cunningham L, Schwartz G. Fixed dose comparison of citalopram versus placebo in the treatment of outpatients with moderate to severe depression. Presented at the 150th Annual Meeting of the American Psychiatric Association, San Diego, CA, May 21, 1997.
15. Bougerol T, Scotto J-C, Patris M, Strub N, Lemming O, Høpfner Petersen HE. Citalopram and fluoxetine in major depression. Clin Drug Invest 1997;14:77-89.
16. Bazett HC. An analysis of the time-relations of electrocardiograms. Hearts 1920;7:353-69.
17. Sandøe E, Sigurd B. Arrhythmia, diagnosis and treatment. St. Gallen, Switzerland: Verlag für Fachmedien, Fach Med AG, 1984.
18. Surawicz B, Uhley H, Borun R, Laks M, Crevasse L, Rosen K, Nelson W, Mandel W, Lawrence P, Jackson L, Flowers N, Clifton J, Greenfield J Jr, De Medina EO. The quest for optimal electrocardiography. Task Force I: standardization of terminology and interpretation. Am J Cardiol 1978;41:130-45.
19. Rebbs de Medina EO, ed. Definition of terms related to cardiac rhythms. WHO/ISFC Task Force. Eur J Cardiol 1978;2:127-44.
20. Rebbs de Medina EO, ed. Classification of cardiac arrhythmias and conduction disturbance. WHO/ISFC Task Force. Am Heart J 1979;98:263-7.
21. Everson SA, Goldberg DE, Kaplan GA, Cohen RD, Pukkala E, Tuomilehto J, Salonen JT. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. Psychosom Med 1996;58:113-21.
22. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. The "vascular depression" hypothesis. Arch Gen Psychiatry 1997;54:915-22.
23. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993; 270:1819-25.
24. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, Refsum HE, Öfsti E, Eriksson S, Syversen D. A controlled multicentre clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-45.
25. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986;32:481-508.
26. Benfield P, Ward A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986;32:313-34.
27. Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985;36:42-4.
28. Upward JW, Edwards JG, Goldie A, Weller DG. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol 1988;26:399-402.
29. Warrington SJ, Dana-Haeri J, Sinclair AJ. Cardiovascular and psychomotor effects of repeated doses of paroxetine: a comparison with amitriptyline and placebo in healthy men. Acta Psychiatr Scand 1989;80[suppl 350]:42-4.
30. Kuhs H, Rudolf GAE. Cardiovascular effects of paroxetine. Psychopharmacology (Berl) 1990;102:379-82.
31. Roos JC. Cardiac effects of antidepressant drugs. A comparison of the tricyclic anti-depressants and fluvoxamine. Br J Clin Pharmacol 1983;15:349S-445S.
32. Klok CJ, Brouver GJ, van Praag HM, Doogan D. Fluvoxamine and clomipramine in depressed patients. Acta Psychiatr Scand 1991; 64:1-11.
33. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990;51:385-6.
34. Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991;52:175-6.
35. Gardner SF, Rutherford WF, Munger MA, Panacek EA. Drug-induced supraventricular tachycardia: a case report of fluoxetine. Ann Emerg Med 1991;20:194-7.
36. Halper JP, Mann JJ. Cardiovascular effects of antidepressant medication. Br J Psychiatry 1988;153:87-98.
37. Roose SP. Modern cardiovascular standards for psychotropic drug. Psychopharmacol Bull 1992;28:35-43.
38. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA 1993;269:2673-5.
39. Personne M, Sjöberg G, Persson H. Citalopram overdose - review of cases treated in Swedish hospitals. Clin Toxicol 1997;35:237-40.
40. Personne M, Sjoberg G, Persson H. Citalopram toxicity. Lancet 1997;350:518-9.
41. Borys DJ, Setzer SC, Ling LJ, Reisdorf JJ, Day LC, Krenzelok EP. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992;10:115-20.
42. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of anti-depressants. BMJ 1995;310:221-4.